Page last updated: 2024-08-23

pravastatin and Response Evaluation Criteria in Solid Tumors

pravastatin has been researched along with Response Evaluation Criteria in Solid Tumors in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Crosse, B; Cullen, M; Fife, KM; Hackshaw, A; Harden, S; Middleton, G; Muthukumar, D; Nash, S; Ngai, Y; Ottensmeier, CH; Schmid, P; Seckl, MJ; Taylor, P; Thompson, J	1

Trials

1 trial(s) available for pravastatin and Response Evaluation Criteria in Solid Tumors

Article	Year
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pravastatin; Response Evaluation Criteria in Solid Tumors; Small Cell Lung Carcinoma; Survival Rate	2017

Article

Year

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pravastatin; Response Evaluation Criteria in Solid Tumors; Small Cell Lung Carcinoma; Survival Rate

2017